Evaxion A (EVAX) Other Non-Current Assets (2019 - 2025)
Evaxion A's (EVAX) quarterly Other Non-Current Assets came in at $185000.0 in Q4 2025, up 14.2% YoY from $162000.0 in Q4 2024, and little changed on a QoQ basis from $185000.0 in Q2 2025.
Evaxion A (EVAX) Other Non-Current Assets (2019 - 2025) Analysis & Trends
Evaxion A (EVAX) has 7 years of Other Non-Current Assets data on file, last reported at $185000.0 in Q4 2025.
- Quarterly Other Non-Current Assets rose 14.2% year-over-year to $185000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $185000.0 (up 14.2% YoY) and the FY2025 annual result came in at $185000.0, up 14.2% from the prior year.
- Other Non-Current Assets was little changed at $185000.0 in Q4 2025, from $185000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $200000.0 in Q2 2021 to a low of $148000.0 in Q2 2022.
- A 5-year average of $175076.9 and a median of $167000.0 in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets dropped 26.0% — and 2025, when it advanced 14.2%.
- Tracing EVAX's Other Non-Current Assets over 5 years: stood at $191000.0 in 2021, then retreated by 18.32% to $156000.0 in 2022, then gained by 7.05% to $167000.0 in 2023, then retreated by 2.99% to $162000.0 in 2024, then grew by 14.2% to $185000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $185000.0 (Q4 2025), $185000.0 (Q2 2025), and $162000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 185,000.00 |
| Jun 30, 2025 | 185,000.00 |
| Dec 31, 2024 | 162,000.00 |
| Jun 30, 2024 | 165,000.00 |
| Dec 31, 2023 | 167,000.00 |
| Jun 30, 2023 | 165,000.00 |
| Dec 31, 2022 | 156,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Mar 31, 2022 | 165,000.00 |
| Dec 31, 2021 | 191,000.00 |
| Sep 30, 2021 | 194,000.00 |
| Jun 30, 2021 | 200,000.00 |
| Mar 31, 2021 | 193,000.00 |
| Dec 31, 2020 | 238,000.00 |
| Dec 31, 2019 | 25,000.00 |